WO2003059264A3 - Methods for the induction of professional and cytokine-producing regulatory cells - Google Patents

Methods for the induction of professional and cytokine-producing regulatory cells Download PDF

Info

Publication number
WO2003059264A3
WO2003059264A3 PCT/US2002/041288 US0241288W WO03059264A3 WO 2003059264 A3 WO2003059264 A3 WO 2003059264A3 US 0241288 W US0241288 W US 0241288W WO 03059264 A3 WO03059264 A3 WO 03059264A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
cytokine
induction
professional
regulatory cells
Prior art date
Application number
PCT/US2002/041288
Other languages
French (fr)
Other versions
WO2003059264A2 (en
WO2003059264A9 (en
Inventor
David A Horwitz
Original Assignee
Univ Southern California
David A Horwitz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California, David A Horwitz filed Critical Univ Southern California
Priority to CA002469800A priority Critical patent/CA2469800A1/en
Priority to EP02799306A priority patent/EP1463799A4/en
Priority to JP2003559429A priority patent/JP2005514054A/en
Priority to AU2002364230A priority patent/AU2002364230B2/en
Publication of WO2003059264A2 publication Critical patent/WO2003059264A2/en
Publication of WO2003059264A3 publication Critical patent/WO2003059264A3/en
Publication of WO2003059264A9 publication Critical patent/WO2003059264A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]

Abstract

The field of the invention is generally related to methods used for the induction of T cells with suppressive activity. More specifically, the methods are sued to generate professional regulatory T cells and cytokine-producing T cells with enhanced suppressive activity.
PCT/US2002/041288 2001-12-21 2002-12-20 Methods for the induction of professional and cytokine-producing regulatory cells WO2003059264A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002469800A CA2469800A1 (en) 2001-12-21 2002-12-20 Methods for the induction of professional and cytokine-producing regulatory cells
EP02799306A EP1463799A4 (en) 2001-12-21 2002-12-20 Methods for the induction of professional and cytokine-producing regulatory cells
JP2003559429A JP2005514054A (en) 2001-12-21 2002-12-20 Methods for the induction of professional and cytokine-producing regulatory T cells
AU2002364230A AU2002364230B2 (en) 2001-12-21 2002-12-20 Methods for the induction of professional and cytokine-producing regulatory cells

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34265501P 2001-12-21 2001-12-21
US60/342,655 2001-12-21
US37410202P 2002-04-19 2002-04-19
US60/374,102 2002-04-19

Publications (3)

Publication Number Publication Date
WO2003059264A2 WO2003059264A2 (en) 2003-07-24
WO2003059264A3 true WO2003059264A3 (en) 2004-02-12
WO2003059264A9 WO2003059264A9 (en) 2004-11-11

Family

ID=26993124

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/041288 WO2003059264A2 (en) 2001-12-21 2002-12-20 Methods for the induction of professional and cytokine-producing regulatory cells

Country Status (5)

Country Link
EP (1) EP1463799A4 (en)
JP (1) JP2005514054A (en)
AU (1) AU2002364230B2 (en)
CA (1) CA2469800A1 (en)
WO (1) WO2003059264A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005212032A1 (en) * 2004-02-12 2005-08-25 Immuno Frontier, Inc Regulatory cell controlling immunological activity of t cell
CA2585462A1 (en) 2004-10-29 2006-05-11 Benaroya Research Institute At Virginia Mason Methods of generating antigen-specific cd4+cd25+ regulatory t cells, compositions and methods of use
EP1933854B1 (en) * 2005-08-31 2014-06-25 ITH Immune Therapy Holdings AB Treatment of inflammatory bowel disease
ITRM20070437A1 (en) * 2007-08-10 2009-02-11 Istituto Naz Per Le Malattie I METHOD FOR THE GENERATION AND EXPANSION OF CELLS T RANGE / DELTA REGULATORY CELLS SOON OBTAINED AND THEIR APPLICATIONS

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0497275A2 (en) * 1991-01-31 1992-08-05 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Generation of CD4+ helper T cells with interleukin 2 and interleukin 4 from L-phenylalanine methyl ester treated human peripheral blood cells
WO2000042856A1 (en) * 1999-01-22 2000-07-27 The Schepens Eye Research Institute, Inc. Activation of regulatory t cells by alpha-melanocyte stimulating hormone
US6228359B1 (en) * 1997-11-05 2001-05-08 University Of Southern California Use of cytokines and mitogens to inhibit pathological immune responses
US20020034500A1 (en) * 2000-08-15 2002-03-21 Levings Megan K. Regulatory T cells; methods
EP1241249A1 (en) * 2001-03-12 2002-09-18 Gerold Schuler CD4+CD25+regulatory T cells from human blood
FR2824567A1 (en) * 2001-05-11 2002-11-15 Inst Nat Sante Rech Med Preparation of antigen-specific Tr1 regulatory lymphocytes, useful for treating inflammatory and autoimmune diseases, uses antigen-presenting cells that express HLA and LFA-3

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759035B2 (en) * 2000-04-11 2004-07-06 University Of Southen California Method to prevent graft rejection using TGF-beta to induce T suppressor cells

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0497275A2 (en) * 1991-01-31 1992-08-05 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Generation of CD4+ helper T cells with interleukin 2 and interleukin 4 from L-phenylalanine methyl ester treated human peripheral blood cells
US6228359B1 (en) * 1997-11-05 2001-05-08 University Of Southern California Use of cytokines and mitogens to inhibit pathological immune responses
WO2000042856A1 (en) * 1999-01-22 2000-07-27 The Schepens Eye Research Institute, Inc. Activation of regulatory t cells by alpha-melanocyte stimulating hormone
US20020034500A1 (en) * 2000-08-15 2002-03-21 Levings Megan K. Regulatory T cells; methods
EP1241249A1 (en) * 2001-03-12 2002-09-18 Gerold Schuler CD4+CD25+regulatory T cells from human blood
FR2824567A1 (en) * 2001-05-11 2002-11-15 Inst Nat Sante Rech Med Preparation of antigen-specific Tr1 regulatory lymphocytes, useful for treating inflammatory and autoimmune diseases, uses antigen-presenting cells that express HLA and LFA-3

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LEVINGS M. ET AL.: "Human CD25+CD4+ T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 193, no. 11, 2001, pages 1295 - 1301, XP002210571 *
YAMAGIWA ET AL.: "The role for TGF-beta in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood", JOURNAL OF IMMUNOLOGY, vol. 166, no. 12, 2001, pages 7282 - 7289, XP002969113 *

Also Published As

Publication number Publication date
EP1463799A4 (en) 2006-01-18
JP2005514054A (en) 2005-05-19
AU2002364230A1 (en) 2003-07-30
EP1463799A2 (en) 2004-10-06
WO2003059264A2 (en) 2003-07-24
AU2002364230B2 (en) 2008-05-01
WO2003059264A9 (en) 2004-11-11
CA2469800A1 (en) 2003-07-24

Similar Documents

Publication Publication Date Title
AU2003248331A1 (en) Hybrid membrane, method for producing the same and use of said membrane
AU2002224927A1 (en) Use of substituted imidazoazines, novel imidazoazines, methods for the production thereof, and agents containing these compounds
ID23374A (en) HALOGENOPIRIMIDIN
WO2003059356A3 (en) Novel anti-infectives
AU2002321292A1 (en) Hybrid membrane, method for the production thereof and use of said membrane
MY133969A (en) Indoloquinazolinones
AU2003218099A1 (en) Modulation of the immune response through the manipulation of arginine levels
WO2000063247A3 (en) Osteopontin-derived chemotactic and inhibitory agents and uses therefor
AU153659S (en) Container
EP1261623A4 (en) New retinol derivatives, the method of preparations and the uses thereof
WO2003059264A3 (en) Methods for the induction of professional and cytokine-producing regulatory cells
AU144678S (en) Bottle
AU2003253437A1 (en) Mesostructured film, porous film and the method of preparing the same
SI1532141T1 (en) 2-PYRROLIDIN-2-YL- ?á1,3,4?å-OXADIAZOLE DERIVATIVES AND THE USE OF THE SAME AS ANTIDEPRESSANTS
AU2001287218A1 (en) The use of melatonin for induction of general anesthesia
AU2002320079A1 (en) Vaccines, immunotherapeutics and methods of using the same
EP1517879A4 (en) Aminoalkylphenols, methods of using and making the same
DE60018253D1 (en) The use of 5-carboxanilido-2,4-bis-trifluoromethylthiazole against rice tanning
AU2002246585A1 (en) Plant promoters, and methods of use
WO2001098512A3 (en) Control of metabolism with compositions of the human 2-oxoglutarate carrier
AU7478098A (en) Methods of treatment using nbs-1, antibodies and proteins thereto, and uses of the antibodies
AU2002352606A1 (en) Eurotinone and derivatives thereof, method for the production and use of the same
WO2004045561A3 (en) Use of ferritin for immunomodulation
AU2001234916A1 (en) Eto1 and related proteins, and methods of regulating ethylene biosynthesis
AU2003304115A1 (en) Dinoflagellate karlotoxins, methods of isolation and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002364230

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2469800

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003559429

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002799306

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002799306

Country of ref document: EP

COP Corrected version of pamphlet

Free format text: PAGES 1/19-19/19, DRAWINGS, REPLACED BY NEW PAGES 1/16-16/16; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE